|
US5525464A
(en)
|
1987-04-01 |
1996-06-11 |
Hyseq, Inc. |
Method of sequencing by hybridization of oligonucleotide probes
|
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
|
US5700637A
(en)
|
1988-05-03 |
1997-12-23 |
Isis Innovation Limited |
Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
|
|
US6054270A
(en)
|
1988-05-03 |
2000-04-25 |
Oxford Gene Technology Limited |
Analying polynucleotide sequences
|
|
US5800992A
(en)
|
1989-06-07 |
1998-09-01 |
Fodor; Stephen P.A. |
Method of detecting nucleic acids
|
|
US5871928A
(en)
|
1989-06-07 |
1999-02-16 |
Fodor; Stephen P. A. |
Methods for nucleic acid analysis
|
|
US5744101A
(en)
|
1989-06-07 |
1998-04-28 |
Affymax Technologies N.V. |
Photolabile nucleoside protecting groups
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
DE69233087T2
(de)
|
1991-11-22 |
2003-12-24 |
Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) |
Verfahren zur Herstellung von Polymerarrays
|
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
|
US5795716A
(en)
|
1994-10-21 |
1998-08-18 |
Chee; Mark S. |
Computer-aided visualization and analysis system for sequence evaluation
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP2298311B1
(en)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
|
US20020065296A1
(en)
|
1999-01-13 |
2002-05-30 |
Bayer Corporation |
Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
|
|
US7141581B2
(en)
|
1999-07-02 |
2006-11-28 |
Agouron Pharmaceuticals, Inc. |
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
|
|
TWI262914B
(en)
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
|
PT1244647E
(pt)
|
1999-11-05 |
2006-10-31 |
Astrazeneca Ab |
Derivados de quinazolina como inibidores de vegf
|
|
CA2395461C
(en)
|
1999-12-22 |
2010-05-25 |
Sugen, Inc. |
Methods of modulating c-kit tyrosine kinase function with indolinone compounds
|
|
HRP20020751B1
(hr)
|
2000-02-15 |
2011-01-31 |
Sugen |
Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
|
|
MXPA03005696A
(es)
|
2000-12-21 |
2003-10-06 |
Glaxo Group Ltd |
Pirimidinaminas como moduladores de angiogenesis.
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP2305255B1
(en)
|
2001-12-03 |
2012-08-22 |
Bayer HealthCare LLC |
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
|
|
SE0104164L
(sv)
|
2001-12-11 |
2003-06-12 |
Ericsson Telefon Ab L M |
Högspännings-mos-transistor
|
|
NO317200B1
(no)
|
2002-08-09 |
2004-09-13 |
Best Practice Deployment As |
System for trafikkopplaering i et kjoretoy
|
|
WO2004029287A2
(en)
|
2002-09-27 |
2004-04-08 |
Oridis Biomed Forschungs- Und Entwicklungs Gmbh |
Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
|
|
US20060019256A1
(en)
*
|
2003-06-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
|
EP2210607B1
(en)
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
GB0411378D0
(en)
|
2004-05-21 |
2004-06-23 |
Astrazeneca Ab |
Pharmaceutical compositions
|
|
AU2006259583A1
(en)
*
|
2005-06-13 |
2006-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
|
CN101506351A
(zh)
*
|
2005-10-21 |
2009-08-12 |
拜尔健康护理有限责任公司 |
用于癌症预测和预后及监测癌症治疗的方法
|
|
US8329408B2
(en)
|
2005-10-31 |
2012-12-11 |
Bayer Healthcare Llc |
Methods for prognosis and monitoring cancer therapy
|
|
EP1954272A2
(en)
|
2005-10-31 |
2008-08-13 |
Bayer Pharmaceuticals Corporation |
Treatment of cancer with sorafenib
|
|
CA2657379A1
(en)
|
2006-07-10 |
2008-01-17 |
Elan Pharma International Ltd. |
Nanoparticulate sorafenib formulations
|
|
EP2074226A2
(en)
*
|
2006-09-19 |
2009-07-01 |
Novartis AG |
Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
|
|
CN105748465A
(zh)
|
2007-07-25 |
2016-07-13 |
卫材R&D管理株式会社 |
用于治疗癌症的多激酶抑制剂
|
|
US20090062347A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched axitinib
|
|
US20090062368A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
|
EP2195286A2
(en)
|
2007-09-10 |
2010-06-16 |
Cipla Limited |
Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
|
|
RU2505603C2
(ru)
|
2007-09-26 |
2014-01-27 |
Чугаи Сейяку Кабусики Кайся |
Антитело против рецептора il-6
|
|
WO2009054004A2
(en)
|
2007-10-22 |
2009-04-30 |
Natco Pharma Limited |
Process for the preparation of sorafenib
|
|
WO2009067686A2
(en)
|
2007-11-21 |
2009-05-28 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
|
|
US20100256392A1
(en)
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
|
EP2252607A2
(en)
|
2008-02-21 |
2010-11-24 |
Generics [UK] Limited |
Novel polymorphs and processes for their preparation
|
|
WO2009106825A1
(en)
|
2008-02-27 |
2009-09-03 |
Cipla Limited |
Polymorphs of sorafenib and salts thereof
|
|
EP2098521A1
(en)
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
|
WO2009111061A1
(en)
|
2008-03-06 |
2009-09-11 |
Sicor Inc. |
Process for the preparation of sorafenib and salts thereof
|
|
CA2720164A1
(en)
|
2008-03-31 |
2009-10-08 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing sunitinib and salts thereof
|
|
KR20110036055A
(ko)
|
2008-06-23 |
2011-04-06 |
낫코 파마 리미티드 |
고순도의 수니티닙 및 이의 약학적으로 허용가능한 염의 개선된 제조 방법
|
|
CA2731605A1
(en)
|
2008-07-24 |
2010-01-28 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib and salts thereof and their polymorphs
|
|
WO2010036796A1
(en)
|
2008-09-26 |
2010-04-01 |
Concert Pharmaceuticals, Inc. |
Pyridineamine derivatives
|
|
CA2704448A1
(en)
|
2008-09-30 |
2010-04-08 |
Teva Pharmaceutical Industries Ltd. |
Amorphous compositions of sunitinib base and l-malic acid
|
|
CA2741087A1
(en)
*
|
2008-10-21 |
2010-04-29 |
Bayer Healthcare Llc |
Identification of signature genes associated with hepatocellular carcinoma
|
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
|
EP2186809A1
(en)
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
|
WO2010059742A1
(en)
*
|
2008-11-18 |
2010-05-27 |
Collabrx, Inc. |
Individualized cancer treatment
|
|
US20100297676A1
(en)
|
2009-05-20 |
2010-11-25 |
Nodality, Inc. |
Methods for diagnosis, prognosis and methods of treatment
|
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
|
JP2012533562A
(ja)
|
2009-07-16 |
2012-12-27 |
グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド |
治療法
|
|
US20120232102A1
(en)
|
2009-09-30 |
2012-09-13 |
Chun-Fang Xu |
Methods Of Administration And Treatment
|
|
CN102665756A
(zh)
|
2009-10-01 |
2012-09-12 |
Csl有限公司 |
费城染色体阳性白血病的治疗方法
|
|
WO2011047019A1
(en)
|
2009-10-13 |
2011-04-21 |
Yale University |
An objective, quantitative method to predict histological subtype in non-small cell lung cancer
|
|
WO2011050159A1
(en)
|
2009-10-23 |
2011-04-28 |
Glaxo Wellcome Manufacturing Pte Ltd |
Compositions and processes
|
|
UY33164A
(es)
|
2010-01-06 |
2011-08-31 |
Glaxo Wellcome Mfg Pte Ltd |
Metodo de tratamiento
|
|
WO2011100325A2
(en)
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
|
WO2011104555A2
(en)
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
|
WO2011128699A2
(en)
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
|
TW201206908A
(en)
|
2010-05-05 |
2012-02-16 |
Glaxo Wellcome Mfg Pte Ltd |
Pharmaceutical compositions and methods of making same
|
|
WO2011146458A1
(en)
|
2010-05-18 |
2011-11-24 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
|
AU2010363613B2
(en)
|
2010-11-01 |
2015-02-05 |
Scinopharm (Kunshan) Biochemical Technology Co., Ltd. |
Processes for the preparation of 3-((pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
|
|
CA2819118A1
(en)
|
2010-11-29 |
2012-06-07 |
Hetero Research Foundation |
A process for the preparation of pazopanib using novel intermediate
|
|
US10220020B2
(en)
|
2010-12-23 |
2019-03-05 |
Nektar Therapeutics |
Polymer-des-ethyl sunitinib conjugates
|
|
WO2012103060A1
(en)
|
2011-01-27 |
2012-08-02 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
|
WO2012116040A1
(en)
*
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
CN102283836B
(zh)
|
2011-06-27 |
2013-01-09 |
苏州大学附属第一医院 |
索拉非尼在制备治疗动脉瘤性自发性蛛网膜下腔出血后发生的早期脑损伤的药物中的应用
|
|
CA2840491A1
(en)
|
2011-06-28 |
2013-01-03 |
Bayer Healthcare Llc |
Topical ophthalmological pharmaceutical composition containing sorafenib
|
|
CN103874770A
(zh)
*
|
2011-08-08 |
2014-06-18 |
卡里斯生命科学卢森堡控股有限责任公司 |
生物标志物组合物和方法
|
|
US20140248372A1
(en)
|
2011-09-19 |
2014-09-04 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
|
TW201531309A
(zh)
|
2011-09-30 |
2015-08-16 |
Pfizer |
Ｎ-甲基-２-〔３-（（ｅ）-２-吡啶-２-基-乙烯基）-１ｈ-吲唑-６-基硫烷基〕苯甲醯胺之藥學組成物
|
|
WO2013090419A1
(en)
*
|
2011-12-12 |
2013-06-20 |
Stc.Unm |
Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia
|
|
WO2013138522A2
(en)
*
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
US11136625B2
(en)
|
2013-08-28 |
2021-10-05 |
Crown Bioscience, Inc. (Taicang) |
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
|